PathKey completes acquisition of Chipforge
ASX-listed PathKey completed its acquisition of Singapore AI-native semiconductor-design company Chipforge.
Evidence notes
- PathKey completed the acquisition of 100% of Chipforge’s issued capital on 23 June 2026.
- Consideration comprised 560 million fully paid PathKey ordinary shares and 150 million performance rights subject to stated vesting milestones.
- Chipforge adds agentic-AI workflows for translating high-level design intent into verified, synthesisable hardware code.
Company context
Pathkey.AI is an ASX-listed technology group spanning AI decision software and AI-native semiconductor design. Formerly Opyl, it operates the TrialKey clinical-development platform and acquired Singapore-based Chipforge in June 2026. Through Chipforge, Pathkey is entering defence and autonomous systems with FPGA prototyping, vision-processing IP and hardware acceleration for mission-critical edge workloads.